Clonidine Versus Adenosine to Treat Neuropathic Pain

Wake Forest University (WFU) logo

Wake Forest University (WFU)

Status and phase

Completed
Phase 2

Conditions

Pain

Treatments

Drug: clonidine
Drug: placebo
Drug: adenosine

Study type

Interventional

Funder types

Other
NIH

Identifiers

NCT00349921
P01NS041386 (U.S. NIH Grant/Contract)
P01NS041386_TRIAL1

Details and patient eligibility

About

The purpose of this study is to determine the effects of clonidine and adenosine on nerve pain.

Full description

This study is part of a pain center grant that focuses on how pain, especially chronic neuropathic pain, alters the response to traditional and non-traditional analgesics (pain medications). Clonidine-a drug commonly used to treat high blood pressure-has been shown to effectively treat neuropathic pain, is FDA-approved for administration via epidural (an injection given in the lower back), and is the third most commonly prescribed drug for chronic intrathecal (an injection into the cerebrospinal fluid) use in people with chronic pain. Adenosine-a drug commonly administered intravenously (into a vein) to treat certain types of abnormal heart rhythms-has been found to reduce areas of allodynia (pain caused by a stimulus that does not normally cause pain) after intrathecal, but not intravenous administration in people with neuropathic pain. Intrathecal clonidine relieves pain by actions on a2-adrenoceptors in the spinal cord, whereas adenosine relieves pain by actions on A1 adenosine receptors. Researchers believe that intrathecal adenosine and clonidine may prove to be excellent painkillers for nerve pain. Therefore, the goal of this study is to determine the effects of clonidine and adenosine on nerve pain. After initial screening, baseline measurements, and training to learn to estimate pain accurately using thermal heat testing, a sample of spinal fluid will be taken from each participant. Participants then will be randomly chosen to receive either clonidine, adenosine, or placebo. After receiving the study medication, participants will be monitored, with their vital signs checked at 30, 60, 120, 180, and 240 minutes. Duration of the study for participants is 2 weeks, and includes two visits to the research center, each lasting approximately 6 hours.

Enrollment

24 patients

Sex

All

Volunteers

No Healthy Volunteers

Inclusion criteria

Patients with complex regional pain syndrome (CRPS), type I involving a lower extremity

Exclusion criteria

  • Pregnancy
  • Allergy to clonidine
  • Currently taking clonidine or other direct a2-adrenergic agonists, or taking cholinesterase inhibitors
  • Patients with any serious or unstable medical problems (heart, lung, liver, kidney, or nervous system disease)

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Crossover Assignment

Masking

Triple Blind

24 participants in 4 patient groups, including a placebo group

clonidine first, then adenosine
Active Comparator group
Description:
clonidine given in first injection adenosine given in second injection
Treatment:
Drug: clonidine
adenosine first, then clonidine
Active Comparator group
Description:
adenosine given in first injection clonidine given in second injection
Treatment:
Drug: adenosine
clonidine given first, then placebo
Placebo Comparator group
Description:
placebo
Treatment:
Drug: placebo
adenosine given first, then placebo
Placebo Comparator group
Description:
placebo
Treatment:
Drug: placebo

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems